- Home
- AIO vs AURA Comparison
AIO vs AURA Comparison
Compare AIO & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIO | AURA |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.8M | 797.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AIO | AURA |
|---|---|---|
| Price | $25.01 | $6.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.60 |
| AVG Volume (30 Days) | 60.5K | ★ 648.1K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.91 | $4.73 |
| 52 Week High | $28.60 | $9.54 |
Technical Indicators
Market Signals| Indicator | AIO | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 37.04 |
| Support Level | $24.07 | $6.05 |
| Resistance Level | $26.79 | $6.27 |
| Average True Range (ATR) | 0.56 | 0.29 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 63.64 | 24.38 |
Price Performance
Historical ComparisonAbout AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.